Anika Therapeutics
ANIK
160 hedge funds and large institutions have $617M invested in Anika Therapeutics in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 52 increasing their positions, 63 reducing their positions, and 17 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $537M → $617M (+$79.4M)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1% less funds holding
Funds holding: 162 → 160 (-2)
17% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 63
27% less call options, than puts
Call options by funds: $2.01M | Put options by funds: $2.76M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.56M |
| 2 |
PCM
Piermont Capital Management
St. Louis,
Missouri
|
+$3.15M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.3M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$2.12M |
| 5 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$7.65M |
| 2 |
FAM
Fred Alger Management
New York
|
-$6.21M |
| 3 |
NAP
New Amsterdam Partners
New York
|
-$4.84M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.74M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$3.66M |
ANIK Hedge Fund Activity: Q2 2016 in Review
160 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2016, worth a combined $617M — up 15% from $537M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ANIK and 16 opened new positions — a net loss of 1 holder — while 63 trimmed existing stakes and 52 added.
The largest buyer was Vanguard Group, adding an estimated $3.56M. The largest seller was Thompson Siegel & Walmsley, cutting an estimated $7.65M.
- 160 institutional investors held Anika Therapeutics (ANIK) as of Q2 2016, down from 162 in Q1 2016.
- Funds reported $617M of Anika Therapeutics stock for Q2 2016, up 15% quarter-over-quarter.
- 16 funds opened new Anika Therapeutics positions in Q2 2016 and 17 closed out, a net change of -1 holder.
- The largest Anika Therapeutics buyer in Q2 2016 was Vanguard Group, an estimated $3.56M added.
- The largest Anika Therapeutics seller in Q2 2016 was Thompson Siegel & Walmsley, an estimated $7.65M sold.
Based on aggregated 13F filings for Q2 2016.